Peregrine Pharmaceuticals (NASDAQ:PPHM) Subsidiary To Participate At Life Sciences Industry Conferences

Peregrine Pharmaceuticals

In the recent biotech stock alerts, Avid Bioservices, Inc., a subsidiary of Peregrine Pharmaceuticals (NASDAQ:PPHM) reported that the firm will mark its presence at two imminent life sciences industry conferences. On March 14, 2017, Mr. David Briggs, Ph.D., will highlight the expanding part of pre-packed columns in biopharma manufacturing as chunk of a case study shown during the Driving Bioprocessing Efficiency session.

The details

Besides acting as a co-sponsor of the conference, Avid will be showcasing its comprehensive range of process advancement and high quality cGMP commercial and clinical manufacturing services for the biopharmaceutical and biotechnology industries. These comprise a variety of unique procedures for generating an extensive range of biopharma product types like highly-glycosylated recombinant enzymes and proteins, monoclonal antibodies, among others. These features also extend to the production of biosimilar offerings and antibody drug conjugate intermediates. They are intended to support the overall current growth of the firm’s contract manufacturing operation.

Company representatives will offer a virtual tour of its advanced commercial bio-manufacturing facility for those interested. This facility is intended to use the most advanced, single-use equipment to house a fully disposable bio manufacturing procedure for late Phase 3 commercial and clinical production of biologics.

Peregrine reported that facility is capable of working in campaign mode whereby numerous bioreactors are concurrently in operation, which develops the facility’s manufacturing competence and capacity.  The Myford centre, which came into existence in 2016, was built to improve Avid’s Franklin facility. The latter has been functional since 1993 and manufacturing cGMP commercial offerings since 2005.

Dr. Briggs will showcase a case study profiling the utilization of exclusive pre-packed supports in a cGMP environment and the influence of this technology on decreasing process time and set-up, as well as validation and capital expense. This case trial will comprise an overview of Myford facility and offer data showcasing the positive influence of pre-packed columns in a manufacturing setting.


Please enter your comment!
Please enter your name here